[{"id":"271e7fdf-8d02-4873-b54f-f0cc79e784c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03406299","created_at":"2021-01-18T14:26:32.423Z","updated_at":"2024-07-02T16:35:50.949Z","phase":"Phase 2","brief_title":"Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer","source_id_and_acronym":"NCT03406299","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" CDKN2A • ARID1A • IL6 • HGF • CXCL1 • CXCL3","pipe":"","alterations":" ","tags":["CDKN2A • ARID1A • IL6 • HGF • CXCL1 • CXCL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • oxaliplatin • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 04/19/2018","start_date":" 04/19/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-04-11"}]